Fox Run Management L.L.C. Takes $474,000 Position in Sarepta Therapeutics, Inc. $SRPT

Fox Run Management L.L.C. acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 27,706 shares of the biotechnology company’s stock, valued at approximately $474,000.

Several other large investors also recently added to or reduced their stakes in the business. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Pandora Wealth Inc. purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter worth $45,000. Brooklyn Investment Group raised its holdings in Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares during the period. Banque Transatlantique SA purchased a new position in Sarepta Therapeutics during the first quarter valued at $44,000. Finally, Hurley Capital LLC grew its holdings in Sarepta Therapeutics by 139.2% during the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 835 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $17.98 on Wednesday. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -20.67 and a beta of 0.52. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The stock’s 50 day simple moving average is $20.28 and its two-hundred day simple moving average is $24.82. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. During the same quarter in the prior year, the firm posted $0.62 EPS. The company’s revenue for the quarter was down 14.5% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRPT has been the topic of several recent research reports. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price target on the stock in a report on Tuesday, July 29th. Morgan Stanley increased their price objective on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 29th. Piper Sandler lifted their target price on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Finally, Leerink Partnrs lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $33.75.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.